| 12:00 PM - 01:00 PM
Room Number : V1000
Pharmacy and Pharmaceutical Sciences Building
12850 East Montview Boulevard
Aurora, CO
CU Innovations and BridgeBio Pharma are partnering to advance novel therapeutics for genetic diseases and oncology. BridgeBio was founded in 2015 to identify and develop treatments that target well-characterized genetic diseases at their source. In service of its mission to bridge the gap between remarkable scientific innovation and patients with unmet needs, BridgeBio has a pipeline of over 20 development programs ranging from early discovery to late-stage development. The CU and BridgeBio partnership will support innovative research into potential therapies by providing resources for proof-ofconcept studies, with the intent of advancing promising candidates into the clinic. Please join us to learn more about how to partner with BridgeBio.

Presented by:

Hannah Shen, PhD
Director, Asset Acquisition, BridgeBio

Dr. Shen leads the business development team in finding, investing, and creating companies in the genetic disease space. She has created BridgeBio companies for several preclinical programs and been involved in acquiring clinical-stage programs.  Dr. Shen’s academic training spans biochemistry (BS, National Taiwan University ’09) and systems neuroscience (Ph.D., Harvard University ’15). Her Ph.D. training was with Dr. Sharad Ramanathan; this work was published, see Kocabas, Shen et al., Nature, 2012.

Kathleen Fleming, PhD
Associate, Asset Acquisition, BridgeBio

Dr. Fleming, a BD team member, champions programs internally for investment into start-ups, company creation, and sponsored research. She has created BridgeBio companies for preclinical programs.  Dr. Fleming’s academic training spans Chemical-Engineering (SB, MIT ’11) and biochemistry (Ph.D., Harvard ’17). Her training was with Dr. Erin O’Shea, who is presently President of HHMI; this work was published, see Fleming and O’Shea, Cell Reports, 2018.

Sign up for news

News interests?